RT Journal Article
T1 Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
A1 La Salvia, Anna
A1 Espinosa Olarte, Paula
A1 Riesco Martínez, María del Carmen
A1 Anton Pascual, Beatriz
A1 García Carbonero, Rocío
AB Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms of increasing incidence and high prevalence due to their relatively indolent nature. Their wide anatomic distribution and their characteristic ability to secrete hormonally active substances pose unique challenges for clinical management. They are also characterized by the common expression of somatostatin receptors, a target that has been extremely useful for diagnosis and treatment (i.e., somatostatin analogues (SSAs) and peptide-receptor radionuclide therapy (PRRT)). Chemotherapy is of limited use for NETs of non-pancreatic origin, and the only approved targeted agents for advanced progressive NETs are sunitinib for those of pancreatic origin, and everolimus for lung, gastrointestinal and pancreatic primaries. Despite recent therapeutic achievements, thus, systemic treatment options remain limited. In this review we will discuss the state-of-the-art targeted therapies in the field of NETs, and also future perspectives of novel therapeutic drugs or strategies in clinical development, including recently presented results from randomized trials of yet unapproved antiangiogenic agents (i.e., pazopanib, surufatinib and axitinib), PRRT including both approved radiopharmaceuticals (177Lu-Oxodotreotide) and others in development (177Lu-Edotreotide, 177Lu-Satoreotide Tetraxetan), immunotherapy and other innovative targeted strategies (antibody-drug conjugates, bites,…) that shall soon improve the landscape of personalized treatment options in NET patients.
PB MDPI
SN 2072-6694
YR 2021
FD 2021-04-03
LK https://hdl.handle.net/20.500.14352/7396
UL https://hdl.handle.net/20.500.14352/7396
LA eng
DS Docta Complutense
RD 6 abr 2025